MEDICAL INDUSTRY NEWS
Untitled Page
Allergan gets FDA approval for new Juvéderm XC
The Irvine-based firm's improved formula provides the same wrinkle treatment but with less pain.
By Tamirra StewartPublished: February 02, 2010 08:45 AM
Irvine-based Botox maker Allergan has received approval from the U.S. Food and Drug Administration for Juvéderm XC, a dermal filler that can also reduce pain during the treatment of facial wrinkles.
The therapy is a new form of Allergan's already FDA-approved Juvéderm injectable gel product. The XC version contains lidocaine, a local anesthetic that provides increased comfort to patients during the treatment of areas such as the nasolabial folds that occur around the nose and mouth. Juvéderm XC provides the same results as the formerly approved product, but the injection experience will be less painful.
The product is touted as the first hyaluronic acid dermal filler approved by the FDA that lasts up to one year after the initial treatment.
“Allergan is committed to providing the latest scientific advancements in facial aesthetic products to meet patients’ demands and further optimize their experiences,” says Robert Grant, the company's corporate vice president and president of Allergan Medical.
NEXT PAGE >>
Related headlines
Irvine's Spectrum stops making enlarged prostate therapy
Irvine-based Neomend raises $30 million
Irvine's Tech Coast Angels ramps up entrepreneurial support
|
||||
|
The therapy is a new form of Allergan's already FDA-approved Juvéderm injectable gel product. The XC version contains lidocaine, a local anesthetic that provides increased comfort to patients during the treatment of areas such as the nasolabial folds that occur around the nose and mouth. Juvéderm XC provides the same results as the formerly approved product, but the injection experience will be less painful. The product is touted as the first hyaluronic acid dermal filler approved by the FDA that lasts up to one year after the initial treatment. “Allergan is committed to providing the latest scientific advancements in facial aesthetic products to meet patients’ demands and further optimize their experiences,” says Robert Grant, the company's corporate vice president and president of Allergan Medical. NEXT PAGE >> Related headlines Irvine's Spectrum stops making enlarged prostate therapy Irvine-based Neomend raises $30 million Irvine's Tech Coast Angels ramps up entrepreneurial support |
||||
